Overview
Alternative Name Teveten, Futuran, Navixen, Regulaten
Lyophilized Powder yes
Source Synthetic
MW: 520.6
Purity: ≥99.9%.
Effective concentration 1-100 nM.
Structure
Chemical name 4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid;methanesulfonic acid.
Molecular formula C24H28N2O7S2.
CAS No.: 144143-96-4
PubChem CID 5282474
Activity Eprosartan inhibits [125I]-angiotensin II binding with IC50 1.4 nM to 3.9 nM in human tissues (adrenal cortex, liver, cloned AT1 receptor) and 1.5 nM to 9.2 nM in rat tissues (e.g. mesenteric artery, adrenal cortex, renal glomerulus). Eprosartan (100 nM) completely blocks angiotensin II-induced isotonic fluid absorption in rabbit isolated perfused proximal convoluted tubules1.
References-Activity
- Plosker G.L. et al. (2000) Drugs. 60, 177.
Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
Solubility 200 mM in DMSO. Centrifuge all product preparations before use (10000 x g 5 min).
Storage of solutions Up to four weeks at 4°C or three months at -20°C.
Our bioassay
Alomone Labs Eprosartan mesylate inhibits the activation of Angiotensin AT1R expressed in CHO-K1-mt Aequorin-Gα16 cells.Dose response curve for the inhibition of AT1R expressed in CHO-K1-mt Aequorin-Gα16 cells. Ca2+ response, as detected by elevation in aequorin derived fluorescence following 0.04 nM Angiotensin II application, was inhibited by increasing concentrations of Eprosartan mesylate (E-145). 5 nM Eprosartan mesylate (E-145) fully inhibited the activation by Angiotensin II.
Target AT1R receptors
Lyophilized Powder
For research purposes only, not for human use
Last Update: 30/03/2021
Specifications
Citations
Citations
